BOCA RATON, Fla.–(BUSINESS WIRE)–May 6, 2019– TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the presentation of results from the Men’s Attitude Toward Menopause Survey (MATE), a large study of men’s understanding of and attitudes related to menopause, at the American College of Obstetricians and Gynecologists 2019 Annual Meeting. The data, representing insights collected from 450 men married to and living with women of menopausal age, uncovered men’s perceptions and attitudes towards menopause and their role in their partner’s menopausal transition.
The MATE survey showed that while men are sensitive to the changes experienced by women during their menopause transition and believe those changes have a negative impact on their relationships, they are less aware of the specific menopausal symptoms or opportunities available for women to get relief from symptoms.
When presented with a list of symptoms that their female partners might be facing, more than half (54%) recognized that their partner was experiencing sleeplessness or difficulty sleeping. Additionally, nearly half reported that their partner was living with a lack of energy (49%), loss of desire for sexual contact (48%), mood swings (47%) and hot flashes (46%). When prompted to select an option, only 55% attributed these symptoms to menopause.
Sixty-three percent of respondents believed their partner’s symptoms had personally affected them with 77% believing the impact was negative to themselves and their relationships (56%). These men acknowledged that symptoms of menopause had a great or negative impact on their partners as it pertained to love making (65%), mood swings (63%) and romance (58%). Some men noted that it was upsetting or frustrating to see their partners going through this transition; however, less than half of respondents were aware that there are treatment options for menopausal symptoms.
“TherapeuticsMD recognizes that menopause is not only a life-transitioning event for women, but also for the men in their lives,” said TherapeuticsMD Chief Medical Officer Sebastian Mirkin. “The MATE survey reveals an opportunity to make that transition easier by helping men better understand symptoms and potential solutions to support their partners in the management of their menopausal symptoms.”
The presentation will be made available on the Investors & Media section of the company’s website at www.therapeuticsmd.com.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA™, BIJUVA™ and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
Source: TherapeuticsMD, Inc.
Vice President, Investor Relations
561-961-1900, ext. 2088